Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: A Veterinary Society of Surgical Oncology retrospective study

Michelle Giuffrida, Debra A. Kamstock, Laura E. Selmic, William Pass, Anna Szivek, Michael B. Mison, Sarah E. Boston, Leslie E. Fox, Cecilia Robat, Janet A. Grimes, Karl C. Maritato, Nicholas J. Bacon

Research output: Contribution to journalArticle

Abstract

Objective: To define and compare clinical characteristics of canine primary appendicular hemangiosarcoma (HSA) and telangiectatic osteosarcoma (tOSA), including signalment, presentation, response to treatment, and prognosis. Study design: Multi-institutional retrospective study. Animals: Seventy dogs with primary appendicular HSA or tOSA. Methods: Patient data were obtained from institutions' medical records. Immunohistochemistry was applied to archived tissues to establish tumor type. Patient characteristics, treatment responses, and outcomes were described and compared by tumor type. Results: Forty-one HSA and 29 tOSA were identified. Dogs with HSA were more likely than dogs with tOSA to be male and have hind limb tumors; 78% of HSA occurred in hind limbs, particularly the tibia. Dogs with tOSA weighed a median of 9.9kg (95% CI 4.6-15.3) more than dogs with HSA. Most dogs received antineoplastic treatment, predominantly amputation with or without adjuvant chemotherapy. Overall survival with local treatment and chemotherapy was 299 days (95% CI 123-750) for HSA and 213 days (95% CI 77-310) for tOSA. Younger age and more aggressive treatment were associated with longer survival in dogs with HSA but not tOSA. One-year survival rates did not differ between dogs with HSA (28%) and those with tOSA (7%). Conclusion: Distinct clinical features were identified between HSA and tOSA in this population. Both tumors were aggressive, with a high incidence of pulmonary metastases. However, local treatment combined with chemotherapy led to an average survival 7 months for tOSA and 10 months for HSA. Clinical significance: HSA should be considered as a differential in dogs with aggressive lytic bone lesions, particularly medium-sized dogs with tibial lesions. HSA has a unique clinical presentation but similar therapeutic response and outcome to OSA. Amputation and chemotherapy appear to prolong survival in some dogs with HSA and tOSA.

Original languageEnglish (US)
JournalVeterinary Surgery
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

hemangiosarcoma
Hemangiosarcoma
osteosarcoma
Osteosarcoma
retrospective studies
Retrospective Studies
Dogs
dogs
drug therapy
neoplasms
Survival
amputation
limbs (animal)
Amputation
Drug Therapy
lesions (animal)
Neoplasms
Therapeutics
Extremities
Adjuvant Chemotherapy

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs : A Veterinary Society of Surgical Oncology retrospective study. / Giuffrida, Michelle; Kamstock, Debra A.; Selmic, Laura E.; Pass, William; Szivek, Anna; Mison, Michael B.; Boston, Sarah E.; Fox, Leslie E.; Robat, Cecilia; Grimes, Janet A.; Maritato, Karl C.; Bacon, Nicholas J.

In: Veterinary Surgery, 01.01.2018.

Research output: Contribution to journalArticle

Giuffrida, M, Kamstock, DA, Selmic, LE, Pass, W, Szivek, A, Mison, MB, Boston, SE, Fox, LE, Robat, C, Grimes, JA, Maritato, KC & Bacon, NJ 2018, 'Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: A Veterinary Society of Surgical Oncology retrospective study', Veterinary Surgery. https://doi.org/10.1111/vsu.12926
Giuffrida, Michelle ; Kamstock, Debra A. ; Selmic, Laura E. ; Pass, William ; Szivek, Anna ; Mison, Michael B. ; Boston, Sarah E. ; Fox, Leslie E. ; Robat, Cecilia ; Grimes, Janet A. ; Maritato, Karl C. ; Bacon, Nicholas J. / Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs : A Veterinary Society of Surgical Oncology retrospective study. In: Veterinary Surgery. 2018.
@article{f6768502502a41dab46022e32a5c683e,
title = "Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: A Veterinary Society of Surgical Oncology retrospective study",
abstract = "Objective: To define and compare clinical characteristics of canine primary appendicular hemangiosarcoma (HSA) and telangiectatic osteosarcoma (tOSA), including signalment, presentation, response to treatment, and prognosis. Study design: Multi-institutional retrospective study. Animals: Seventy dogs with primary appendicular HSA or tOSA. Methods: Patient data were obtained from institutions' medical records. Immunohistochemistry was applied to archived tissues to establish tumor type. Patient characteristics, treatment responses, and outcomes were described and compared by tumor type. Results: Forty-one HSA and 29 tOSA were identified. Dogs with HSA were more likely than dogs with tOSA to be male and have hind limb tumors; 78{\%} of HSA occurred in hind limbs, particularly the tibia. Dogs with tOSA weighed a median of 9.9kg (95{\%} CI 4.6-15.3) more than dogs with HSA. Most dogs received antineoplastic treatment, predominantly amputation with or without adjuvant chemotherapy. Overall survival with local treatment and chemotherapy was 299 days (95{\%} CI 123-750) for HSA and 213 days (95{\%} CI 77-310) for tOSA. Younger age and more aggressive treatment were associated with longer survival in dogs with HSA but not tOSA. One-year survival rates did not differ between dogs with HSA (28{\%}) and those with tOSA (7{\%}). Conclusion: Distinct clinical features were identified between HSA and tOSA in this population. Both tumors were aggressive, with a high incidence of pulmonary metastases. However, local treatment combined with chemotherapy led to an average survival 7 months for tOSA and 10 months for HSA. Clinical significance: HSA should be considered as a differential in dogs with aggressive lytic bone lesions, particularly medium-sized dogs with tibial lesions. HSA has a unique clinical presentation but similar therapeutic response and outcome to OSA. Amputation and chemotherapy appear to prolong survival in some dogs with HSA and tOSA.",
author = "Michelle Giuffrida and Kamstock, {Debra A.} and Selmic, {Laura E.} and William Pass and Anna Szivek and Mison, {Michael B.} and Boston, {Sarah E.} and Fox, {Leslie E.} and Cecilia Robat and Grimes, {Janet A.} and Maritato, {Karl C.} and Bacon, {Nicholas J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/vsu.12926",
language = "English (US)",
journal = "Veterinary Surgery",
issn = "0161-3499",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs

T2 - A Veterinary Society of Surgical Oncology retrospective study

AU - Giuffrida, Michelle

AU - Kamstock, Debra A.

AU - Selmic, Laura E.

AU - Pass, William

AU - Szivek, Anna

AU - Mison, Michael B.

AU - Boston, Sarah E.

AU - Fox, Leslie E.

AU - Robat, Cecilia

AU - Grimes, Janet A.

AU - Maritato, Karl C.

AU - Bacon, Nicholas J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To define and compare clinical characteristics of canine primary appendicular hemangiosarcoma (HSA) and telangiectatic osteosarcoma (tOSA), including signalment, presentation, response to treatment, and prognosis. Study design: Multi-institutional retrospective study. Animals: Seventy dogs with primary appendicular HSA or tOSA. Methods: Patient data were obtained from institutions' medical records. Immunohistochemistry was applied to archived tissues to establish tumor type. Patient characteristics, treatment responses, and outcomes were described and compared by tumor type. Results: Forty-one HSA and 29 tOSA were identified. Dogs with HSA were more likely than dogs with tOSA to be male and have hind limb tumors; 78% of HSA occurred in hind limbs, particularly the tibia. Dogs with tOSA weighed a median of 9.9kg (95% CI 4.6-15.3) more than dogs with HSA. Most dogs received antineoplastic treatment, predominantly amputation with or without adjuvant chemotherapy. Overall survival with local treatment and chemotherapy was 299 days (95% CI 123-750) for HSA and 213 days (95% CI 77-310) for tOSA. Younger age and more aggressive treatment were associated with longer survival in dogs with HSA but not tOSA. One-year survival rates did not differ between dogs with HSA (28%) and those with tOSA (7%). Conclusion: Distinct clinical features were identified between HSA and tOSA in this population. Both tumors were aggressive, with a high incidence of pulmonary metastases. However, local treatment combined with chemotherapy led to an average survival 7 months for tOSA and 10 months for HSA. Clinical significance: HSA should be considered as a differential in dogs with aggressive lytic bone lesions, particularly medium-sized dogs with tibial lesions. HSA has a unique clinical presentation but similar therapeutic response and outcome to OSA. Amputation and chemotherapy appear to prolong survival in some dogs with HSA and tOSA.

AB - Objective: To define and compare clinical characteristics of canine primary appendicular hemangiosarcoma (HSA) and telangiectatic osteosarcoma (tOSA), including signalment, presentation, response to treatment, and prognosis. Study design: Multi-institutional retrospective study. Animals: Seventy dogs with primary appendicular HSA or tOSA. Methods: Patient data were obtained from institutions' medical records. Immunohistochemistry was applied to archived tissues to establish tumor type. Patient characteristics, treatment responses, and outcomes were described and compared by tumor type. Results: Forty-one HSA and 29 tOSA were identified. Dogs with HSA were more likely than dogs with tOSA to be male and have hind limb tumors; 78% of HSA occurred in hind limbs, particularly the tibia. Dogs with tOSA weighed a median of 9.9kg (95% CI 4.6-15.3) more than dogs with HSA. Most dogs received antineoplastic treatment, predominantly amputation with or without adjuvant chemotherapy. Overall survival with local treatment and chemotherapy was 299 days (95% CI 123-750) for HSA and 213 days (95% CI 77-310) for tOSA. Younger age and more aggressive treatment were associated with longer survival in dogs with HSA but not tOSA. One-year survival rates did not differ between dogs with HSA (28%) and those with tOSA (7%). Conclusion: Distinct clinical features were identified between HSA and tOSA in this population. Both tumors were aggressive, with a high incidence of pulmonary metastases. However, local treatment combined with chemotherapy led to an average survival 7 months for tOSA and 10 months for HSA. Clinical significance: HSA should be considered as a differential in dogs with aggressive lytic bone lesions, particularly medium-sized dogs with tibial lesions. HSA has a unique clinical presentation but similar therapeutic response and outcome to OSA. Amputation and chemotherapy appear to prolong survival in some dogs with HSA and tOSA.

UR - http://www.scopus.com/inward/record.url?scp=85051190539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051190539&partnerID=8YFLogxK

U2 - 10.1111/vsu.12926

DO - 10.1111/vsu.12926

M3 - Article

C2 - 30051473

AN - SCOPUS:85051190539

JO - Veterinary Surgery

JF - Veterinary Surgery

SN - 0161-3499

ER -